Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances Short-Term Debt repayments Wages, Salaries and Other

Journey Medical (DERM) Long-Term Debt Issuances (2022 - 2024)

Journey Medical filings provide 2 years of Long-Term Debt Issuances readings, the most recent being $5.0 million for Q4 2024.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $5.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $10.0 million, a N/A change, with the full-year FY2024 number at $10.0 million, down 33.33% from a year prior.
Long-Term Debt Issuances hit $5.0 million in Q4 2024 for Journey Medical, up from -$50000.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $14.8 million in Q1 2022 to a low of -$50000.0 in Q3 2024.